Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis

Inclusion Criteria: * Age: \>40 years at the time of study inclusion * Preserved gait capability, with or without assistive devices * Symptomatic hip arthropathy with a disease evolution of at least 1 year. * Radiographic Kellgren-Lawrence grade II-III documented within the 12 months prior to study entry * Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score \>15 * Patient currently receiving intra-articular hyaluronic acid treatment within 3 months prior to study inclusion Exclusion Criteria: * Refusal to provide written informed consent * Females who are pregnant, breastfeeding, or not using effective contraception * Body Mass Index (BMI) ≥ 30 kg/m² * Presence of other chronic or autoimmune diseases that could interfere with clinical evaluation * History of hypersensitivity or allergy to hyaluronic acid or its derivatives * Prior administration of intra-articular platelet-rich plasma (PRP) or intra-articular corticosteroids within 3 months, or intra-articular hyaluronic acid within 6 months prior to study entry